{"ticker": {"uuid": "fee8a675-5ed9-4b93-a020-12b4b308e34e", "symbol": "AKTX", "name": "Akari Therapeutics PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 4 Akari Therapeutics PLC For: 17 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNS3JYR2FKRllVSmN2eGM2U09mcUxpRGFCVlI2RkhjTEhIUUhyMzNxMDNZOXQwX1JBeGtORmZoZGNHVVdOcnpIZm1FdmdDZEN6NjNWc2poYWwtTm1UX296X2ZjaUY0aTU2WEFrM3B4ZW1SWHZUNjNOeUxWRFZ6cERjMktMRW1zdkcwTkZGb1Z1MHhXR2pRNVhKWGdmMGNOYnQwREhzQg?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T11:06:43+00:00", "published_display": "17 Jul 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) director exercises pre-funded warrants for 22,474 ADSs", "summary": "Akari Therapeutics director Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026, to acquire 22,474 American Depositary Shares (ADSs). These exercises involved different price points ($0.0004 and $8.00 per ADS) and were not part ", "url": "https://www.stocktitan.net/sec-filings/AKTX/form-4-akari-therapeutics-plc-insider-trading-activity-dcb548feb591.html", "source_name": "Stock Titan", "published_at": "2026-07-17T09:40:22", "published_display": "17 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Akari Therapeutics (AKTX) Q4 2025 earnings summary", "summary": "Akari Therapeutics (AKTX) reported a Q4 2025 summary highlighting its strategic shift to next-generation antibody-drug conjugates (ADCs) following the acquisition of Peak Bio. The company's lead candidate, AKTX-101, is in preclinical development with a projected Phase 1 trial sta", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-q4-2025_FPwe6lo4", "source_name": "Quartr", "published_at": "2026-07-16T13:40:23", "published_display": "16 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Proxy filing Summary", "summary": "Akari Therapeutics has released a summary of its upcoming 2026 Annual General Meeting (AGM), scheduled for June 30, 2026. The meeting will address 18 resolutions covering financial, governance, compensation, and capital matters, with the Board unanimously recommending a \"for\" vot", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-proxy-filing_FPweVxlU", "source_name": "Quartr", "published_at": "2026-07-16T04:11:56", "published_display": "16 Jul 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Q1 2026 earnings summary", "summary": "Akari Therapeutics (AKTX) reported a Q1 2026 net loss of $14.5 million, significantly higher than Q1 2025 due to non-cash impairment charges. The company is focused on advancing its lead ADC program, AKTX-101, towards a Phase 1 trial by mid-2027 but faces substantial doubt about ", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-q1-2026_FPweVime", "source_name": "Quartr", "published_at": "2026-07-16T03:11:56", "published_display": "16 Jul 2026 03:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Akari Therapeutics Plc SEC Filing", "summary": "Akari Therapeutics Plc (AKTX) has had an [EFFECT] SEC Filing, indicating the effectiveness of its S-3 shelf registration statement. This filing, accepted by EDGAR on July 14, 2026, and effective on July 13, 2026, allows the company flexibility in future offerings. The filing's se", "url": "https://www.stocktitan.net/sec-filings/AKTX/effect-akari-therapeutics-plc-sec-filing-325b521b90a1.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:11:56", "published_display": "15 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com", "summary": "This article announces the filing of Form S-3/A by Akari Therapeutics PLC on July 10. It is a brief, one-line report from Investing.com, providing basic information about the SEC filing. The article does not contain further details about the content of the S-3/A filing.", "url": "https://ng.investing.com/news/stock-market-news/form-s3a-akari-therapeutics-plc-for-10-july-93CH-2595513", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:38", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement", "summary": "Akari Therapeutics Plc (NASDAQ: AKTX) has filed an amended shelf registration to allow existing holders to resell up to 5.99 million American Depositary Shares (ADSs), representing approximately 479.99 billion ordinary shares. These ADSs originate from a private placement in May ", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-a-akari-therapeutics-plc-amended-shelf-registration-statement-4ee48cfb7f35.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:18", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics(AKTX) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxQajJ6SThaUkgyNTItRDlXTWxiZjBQVXhmcVFnNDI4SlBmMHUzTGhnTFhfTk9fX3NqT2lnRkFiWW9UdWFFMTFoTXdYRmoxVHpHc19zbjlTZWJzYnFEZm80bkc3ZTZFVkpFbTNWNzZNUUNLR3J3cmJpd2pidmhDUV81YVlFUXdDRjMzTlFNdGlmQXpacTB2eERDTThSeXctTHdQSWxiWmRkNlRKSkNPcTAwNVhEdUxtVVJSZUR4eXZObE1ZaFIzdk1aQ3lxSHhHZUEtVlo1dVN2SFBXRWRYSjkxSHNmcG5xelJ1cTF0YWxGTFN3QTNkQmo3cVBqQVpxV19tYl9qMm11SThsbjZ0b2VlV2twQjVEYUVVeVhMNmRwbnA4Q2wyUGtUZW9EZzhydw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T15:58:19+00:00", "published_display": "09 Jul 2026 15:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) adds private\u2011placement warrants and purchase agreement exhibits", "summary": "Akari Therapeutics (NASDAQ: AKTX) has amended its S-3 registration statement to file exhibits, including amended Articles of Association, deposit agreement documents for American Depositary Shares, various warrant forms (Pre-Funded, Series H, I, and J), and the Securities Purchas", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-a-akari-therapeutics-plc-amended-shelf-registration-statement-e79c70792202.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:03", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Appoints Former AACR President and", "summary": "Akari Therapeutics has appointed Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase oncology clinical development will be instrumental as Akari advances", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323219/0/en/akari-therapeutics-appoints-former-aacr-president-and-renowned-oncology-drug-development-leader-patricia-lorusso-d-o-to-scientific-advisory-board.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T22:49:33", "published_display": "07 Jul 2026 22:49", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNTFNUTWNWY2NqQUNPNDlHT0J4MlZQTWVmbGtoQVlNYTlJMDRueFBzWm55U0ZBM19IYWVuTUgzSk9qMG44U2RDY1lNUHBQMmU3NjY4X3ZveUhGdV8tbDFvTjFUbzREdUdQOTJ5M1drYkluRWtkbDduNHpQVkF3bHBrU1dNUnJpaUhaM0lJWmRXYlpBOGVLQ1JqMFFkQVNtMmZUT0x2eGFrMzlvUFBjeHAySWNNck9YMjgzU2ZGRENaTXZZaUlFem5JMnI5SVpBWHh5b2J5ank0enRqSFNJREcxanlCLUYxUlhqYUM2bmZtSDZuZWVuSDVj?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T21:20:19+00:00", "published_display": "07 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari adds former AACR president Patricia LoRusso to advisory board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPVzNXZHFIVnJ1MTN5eVR1OFpBYm04MDc1S1ZkZUU2MTFDdTVLVVJUcFR0TlNxNVhMSXlPZkM2S0FEbzFfSHlGVV83ZmNTTWNaeEhfOHZ3Y0FERDNOSjkwaXExcE1fdlJnMnlTQ0tUWWY1VDRFbVB2YTFTNFBicE4xUW5IbnRERjdIakt1UDFwU2dwYzgySlltSUI4NTFPZEJ4N25UNWZnMnd3VTQtOU56VkJkSkJwV3Rt?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T12:55:00+00:00", "published_display": "07 Jul 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board", "summary": "Akari Therapeutics, an oncology biotechnology company, announced the appointment of Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase clinical developm", "url": "https://www.finanznachrichten.de/nachrichten-2026-07/68963740-akari-therapeutics-plc-akari-therapeutics-appoints-former-aacr-president-and-renowned-oncology-drug-development-leader-patricia-lorusso-d-o-to-sc-399.htm", "source_name": "FinanzNachrichten.de", "published_at": "2026-07-07T13:09:32", "published_display": "07 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board", "summary": "Akari Therapeutics, an oncology biotechnology company, has appointed Dr. Patricia LoRusso, a globally recognized leader in oncology drug development, to its Scientific Advisory Board. Dr. LoRusso's extensive expertise will be crucial as Akari advances its lead candidate, AKTX-101", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323219/0/en/Akari-Therapeutics-Appoints-Former-AACR-President-and-Renowned-Oncology-Drug-Development-Leader-Patricia-LoRusso-D-O-to-Scientific-Advisory-Board.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T12:41:30", "published_display": "07 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside", "summary": "Akari Therapeutics (AKTX) shares surged over 133% after reporting positive preclinical data for its lead cancer therapy, AKTX-101, and announcing a $5.5 million private placement. AKTX-101 showed strong results in pancreatic cancer cells when combined with an existing drug. The c", "url": "https://stocktwits.com/news-articles/markets/equity/aktx-stock-goes-parabolic-after-hours-on-capital-raise-cancer-data-win/cZgbrxiRe8F", "source_name": "Stocktwits", "published_at": "2026-07-07T11:09:32", "published_display": "07 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) AGM OKs new share issuances and board changes", "summary": "Akari Therapeutics shareholders approved several key proposals at their June 30, 2026 Annual General Meeting, including the 2025 financial statements, most director re-elections, and the appointment of auditors. Critically, shareholders also approved significant equity-related it", "url": "https://www.stocktitan.net/sec-filings/AKTX/8-k-akari-therapeutics-plc-reports-material-event-dc3de81ad81e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:06", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Akari Therapeutics PLC For: 2 July By Investing.com", "summary": "Akari Therapeutics PLC filed a Form S-3 on July 2nd. The article provides the filing information and mentions that the company's stock symbol is AKTX, which was up 1.56% at the time of publication. The content itself seems to be a template for financial news with many market data", "url": "https://ca.investing.com/news/stock-market-news/form-s3-akari-therapeutics-plc-for-2-july-93CH-4719213", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:41:06", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each", "summary": "Akari Therapeutics (NASDAQ: AKTX) has registered 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares, for resale by selling shareholders. These ADSs arise from a May 2026 private placement and include shares issuable upon the exercise of vari", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-akari-therapeutics-plc-shelf-registration-statement-b0633e0d7426.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:20", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics PLC has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC)", "summary": "Akari Therapeutics PLC has filed a prospectus supplement with the SEC concerning the resale of up to 6 million American Depositary Shares (ADS) by existing shareholders. These ADS represent up to 48 billion ordinary shares. The company will not receive any proceeds from this tran", "url": "https://www.bitget.com/amp/news/detail/12560605487904", "source_name": "Bitget", "published_at": "2026-07-02T09:11:01", "published_display": "02 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones", "summary": "Akari Therapeutics announced the completion of its $5.5 million PIPE early by consolidating remaining funding tranches, along with an additional $2.8 million from warrant exercises, totaling approximately $8.3 million in Q2 2026. This capital injection strengthens the company's f", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/akari-therapeutics-completes-previously-announced-pipe-strengthening-balance-sheet-ahead-of-potential-key-clinical-and-regulatory-milestones/2374900", "source_name": "The Manila Times", "published_at": "2026-06-30T08:39:11", "published_display": "30 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics completes $8.3m capital raise in Q2", "summary": "Akari Therapeutics Plc (NASDAQ:AKTX) successfully completed a private placement and warrant exercises, raising approximately $8.3 million in total capital during the second quarter of 2026. This capital infusion is significant for the oncology biotechnology company, which is deve", "url": "https://www.investing.com/news/company-news/akari-therapeutics-completes-83m-capital-raise-in-q2-93CH-4765464", "source_name": "Investing.com", "published_at": "2026-06-30T08:09:13", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTX - Akari Therapeutics Plc ADR Options", "summary": "This article provides a detailed financial overview of Akari Therapeutics Plc (AKTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutiona", "url": "https://finviz.com/stock?t=AKTX&p=m&ty=oc&r=y5&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-06-29T20:41:01", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Completes Previously Announced PIPE,", "summary": "Akari Therapeutics announced the completion of its $5.5 million PIPE combined with an additional $2.8 million from warrant exercises, totaling $8.3 million in Q2 2026. This funding strengthens the company's balance sheet, supporting the advancement of its lead candidate AKTX-101 ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318968/0/en/akari-therapeutics-completes-previously-announced-pipe-strengthening-balance-sheet-ahead-of-potential-key-clinical-and-regulatory-milestones.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com", "summary": "Akari Therapeutics (NASDAQ: AKTX) has successfully completed an $8.3 million capital raise in Q2 2026, comprising a $5.5 million private investment in public equity (PIPE) led by existing investors and $2.8 million from warrant exercises. This funding is critical for the oncology", "url": "https://ca.investing.com/news/stock-market-news/akari-therapeutics-completes-83m-capital-raise-in-q2-93CH-4711813", "source_name": "Investing.com Canada", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari locks in $8.3M to fund cancer drug trial push", "summary": "Akari Therapeutics announced the completion of an $8.3 million funding round in Q2 2026, comprising a $5.5 million PIPE and $2.8 million from warrant exercises. This capital infusion is intended to advance its lead drug candidate, AKTX-101, towards a Phase 1 clinical trial and pr", "url": "https://www.stocktitan.net/news/AKTX/akari-therapeutics-completes-previously-announced-pipe-strengthening-jebqw2qjgozp.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com", "summary": "This article announces that Akari Therapeutics PLC filed a Form S-1/A on June 26. The news is brief and directly states the filing, indicating it's a financial regulatory update for the company. The article also includes various market data and related news not directly tied to t", "url": "https://ng.investing.com/news/stock-market-news/form-s1a-akari-therapeutics-plc-for-26-june-93CH-2576646", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T19:40:12", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Amends Securities Purchase Agreement in June 2026 \u2013 Key Details from Latest 8-K Filing", "summary": "Akari Therapeutics, Plc has amended its Securities Purchase Agreement, consolidating the second and third closings into a single \"Combined Closing\" for an aggregate investment. This amendment, detailed in a Form 8-K filing, requires shareholder approval at the company's annual ge", "url": "https://www.minichart.com.sg/2026/06/27/akari-therapeutics-amends-securities-purchase-agreement-in-june-2026-key-details-from-latest-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-27T01:09:27", "published_display": "27 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Consolidates Private Placement Closings; Issues 980,395 ADSs in Final Tranche", "summary": "Akari Therapeutics (AKTX) has amended its Securities Purchase Agreement to consolidate the second and third closings of its private placement into a single closing on June 26, 2026. The company issued 980,395 additional ADSs (or prefunded warrants) in this final tranche, bringing", "url": "https://www.tradingview.com/news/tradingview:3e5c2f35a9d9d:0-akari-therapeutics-consolidates-private-placement-closings-issues-980-395-adss-in-final-tranche/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:27", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) consolidates private placement closings, issues remaining ADSs", "summary": "Akari Therapeutics (NASDAQ: AKTX) has amended its securities purchase agreement to combine the second and third closings of a private placement into a single consolidated closing on June 26, 2026. This private placement involves 1,470,588 unregistered American Depository Shares (", "url": "https://www.stocktitan.net/sec-filings/AKTX/8-k-akari-therapeutics-plc-reports-material-event-a146d446be88.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:27", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX)", "summary": "This page on TradingView provides financial actuals and estimates for Akari Therapeutics Plc (NASDAQ: AKTX). Users can explore reported financial data and analyst estimates, across various financial statements and valuation metrics. The platform allows for comparison of actual re", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:40:35", "published_display": "26 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Akari Therapeutics PLC For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU01YVnk4NkVhYXhTajAzX0twVEVZWmNRV1dPbEN1U3JaZExER1ZlZnJKbENCckxLWjZPSDgyRF9NU3JrYVo5SzZRQm9YbjZoUnlPR2VvODEwYVpRd3lZandjbEdyZGtVQW13M3NXOUthVkhBeWY3Zy1OcXB5VVh0a2JyRWNDNTBCX1lkRlA5UDNlR0VYQXNITUduNk9EdTdicW5QOA?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-26T01:21:14+00:00", "published_display": "26 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Akari Therapeutics Stock Is Falling On Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOcjBRcTFlWnRHeVg5TktFaVk0cjItRUkzMHNiS2pDTUFOUlR5SFE1UTIyaURFbHNxaGRYYWk1SmNTbGJkZTVxSDRvN0ZPdXZKLUdMNHgwanlhb2JTQ2p2RUlGdVFIdkE2SzVLMjlNMGRnbUtsQ1hLVkozdHdzWFRVOVBucFRiR1ZZZVpXMHg2VXcxb1Bua0Y1amtXRDMyNDNYX203RFRPWTNHdFktT3VDQQ?oc=5", "source_name": "Benzinga", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPNFFuQTlMeWNFandpN1dITUNYZFhCTVRhNDl0UF9QZldJdEZJZjk4cWF0NEw5U0xuRDBwSURkQXMxYkpxT0t5cU9Venk0TTUzWGVZMk10bDBOdWlUUm5hNUs1SnVUWF9rbGZlaTFlOS1zOGRJVGdELUpiNk92bTQyd3hkNy1TVHFKaXh6UkkwMVRjVy13bmpLX2pwN3E0RlVnb2tkbHlmRmRHNmZkYmh3WkZUQjdmSUFCUjZ3dlVXU1pFWWoxbWo2dVhJZmRySEpibGlsVjdDbGYzVEcydlFtSDdTZW4wanM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$5.5M raise to push Akari cancer drug toward first human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPWEpseGJYY0xUMURZeVh2NXBYbXMwZ3pXd0lrdkpnTzlkOEFMQTlHOW1vMU1KMmJZcnhvbE5BNjNwMUxuSFNFdllVUThUbm5NYUNiMlJTeDVBQ3p0X2RpZmpXdUY5UVIyNVhqN19DRUtPUFlQZ1ZJcWtTaXlIVDVMWkk4N2NoeFBJRGw1OGRfb1FVcExTZHRoWkFxLThUZkd6dFkwa1h1TFhZMW0zeFBTSXNBMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics stock rockets 50% higher on KRAS combination data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWGYzODYzZUJBeDNBcmJieHRSSElvRnV0ZER1MUpqb1FFRDdYZ3VIY05CanU5VmxXS1lqU3VNYUdJc28zTXpham04ZFM1dnRSRWRlTW91a0xIQkdFakxuSXhGWVN3MHdzQ0JKRUZ2T0pZdF9uUkF1TkUwaXhvektJSmNJOHhJNW9pMW5WSzdmTjlOV0l2eXJUSVdSV09vOVJqUkl3X2U2UW8tRVhEOHV3WW9JYXUtT1A1Ymx3ZWdKd3BqVFdld3Vrbg?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Shares Surge 120% on Promising Preclinical Cancer Therapy Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPRVBlYldtOFR1QUl5V3F0b2dsdnY4OUpxT0lUNVZxSUw5cklvNEZDaUJHUmpnV1BJMU55bnkwZGpfSHEzeHo3QTlvY0ZXdktXb05zUUtqTlJyc1ZrVDlZOGVheHJRUTNrazhpWWJBTkRTTTIwZ3FaRXNrRkZXN3MwaS14ZE0zY2JISlpIODlJNVFuUFJfXzJFemZVY0d2X0VkekRUSURPZmh4dXY2UDJwNUlCWnd3clc1OWI5S2Z3QnpOZEFxcFBkWTA3aWFNYmF2bkE?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[RW] Akari Therapeutics Plc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNNkI3dlRnN1ZtMzlJZGRxVmlzei1IbWdqemRUNG9WOTVBMDZLQjhVX3BxMGV5LXc2bU5ZVGhIVmtsb1hyS25MZTRmYUVZNUdkYlctaTNBMTBIc1RaemZGVGZRM3VWLXpDWWNfaGEtN0MyQjlpYjFOa09ReUw0Q2hlOG1teWcxWklNY0QwcF9PN2FWQl95NnBhbWpsbGJXblU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental Akari drug boosts KRAS blocker in pancreatic cancer cells", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaUF5N2ozOUJGUDlYOE5wVWRZa05hV3lGck5YMlh3cy1YRmV2X1JncTg2V01ybDc1bVFqOGRHOHF4WU9TY1QxMXRzb3VLYWk1djZJbEZIM2plM3BBNnQ5dHByeEIwTXlBUzZEa0hDYlhGMUx1MjkxTjlsdnJFVTd4RXVvc0NZYmNhbmhQYkZRb1hvaE5vSW5UUXlxaXYwQnNOTGwtbUhZZE5iZmNqVHRCVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Akari adds Australian patent cover for payload behind two cancer programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNV2JFbVN0ZjJFRjZackhubVZ2MkE3N2w0M1JodTMyTm5ZUnFVVlAtU0J2X0liTmZXYXdoRHhiNjR4dHNkZFdlaTRhWkNIczVXcGk5WVlldUx4ZUtJTU40VTZtMGdsc2lCT2VvbmVPUk4wMTlURDF6OWo0V0IzNG1qZm1mLTJqTm1pUmZfclViUm1GTXk2bG85VUdIaVR0LTNYeTRkVDdDN1EyNUM5alYwbFdyR2oya1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bladder, lung and breast models show Akari drug beats TROP2 rivals", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWXBERFpjTjVTSjkzVUdwUGh4TmsyV1hfU2JYV3RjdlJwQXJ2aE5XTnYtc0dKWFpUUkhmRXVwYnNWbGRVeHpsZmRHOTFlZkZjRThvbHUxRGdicXlnSUhDblZGVkxFMHRRM1ZWdmpQSWZWcDM2S1VIc1Fwa1FZejIxNWNZNUZsUW1uMXZLZkF5NGlZdHJBRXdJaTFCQW1LUGotajNGdXhiZ29PU3lfMU5yRlBJbWZyeUlfa2ZmbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cancer biotech Akari charts new ADC toward first human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPVlZLTG1GcUk0MXpxMGp1cjdGbWk3WWU4ZmRvZmhDeVBJdU5pUDctdzdzSlR4Qy1rRVkzVWM4ZlNMdjBraDVEMDVTVkxJUm5yeU50Z080UG91WTJVODk3OVIwZXpOckhrVk9oV2E0V0VhdXlrektRTG9FQmxidk51ZEh6TGJRUWF3RE1RV0kyYlQ3RS1veXhtbWNNc3lod2pjeEwya3RrYmFIRUVfUlJoVWxlNWxOdVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Purchased US$1.81m Of Akari Therapeutics Stock May Not Have Expected 36% Tumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE91UXVJV2l5dF9rNnUzcDZObGVLdW9ENTBaOWgxVktHeTduQVNJb3MwbldyM0tQR29wLVRxSWlCZVhDak55SE4ydVRpd0RfQ29iN0hqa3dkRDFQNVhKbG1sRHRWckhvS2p6WUR2QnBtX0RUQ3J5YWJTazFXNTF3QQ?oc=5", "source_name": "Market source", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc (AKTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBMUTFxRmkta3NHcS00Ylk0SVo5aTRMSUlBY3pYV2hMNUVtSDZaNWk0U1ZqM21sSVdRQnhWTFNmNWI4Z0lTNEFJUGllSWNlRHN5bmtz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:27:43+00:00", "published_display": "25 Apr 2025 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1oaW1aQ0NKWW5OQUZUbVo1ZjBVNzFrUXJwSHZNNmhZMnNzaHM4MkJvR0VIaVdxbGJNck5RZ3ZrYzBGUmFzZU5Vd0JabEFMUUJjemFxTmI1bFFxQQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-11T23:18:55+00:00", "published_display": "11 Aug 2016 23:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Akari Therapeutics PLC For: 17 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNS3JYR2FKRllVSmN2eGM2U09mcUxpRGFCVlI2RkhjTEhIUUhyMzNxMDNZOXQwX1JBeGtORmZoZGNHVVdOcnpIZm1FdmdDZEN6NjNWc2poYWwtTm1UX296X2ZjaUY0aTU2WEFrM3B4ZW1SWHZUNjNOeUxWRFZ6cERjMktMRW1zdkcwTkZGb1Z1MHhXR2pRNVhKWGdmMGNOYnQwREhzQg?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T11:06:43+00:00", "published_display": "17 Jul 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) director exercises pre-funded warrants for 22,474 ADSs", "summary": "Akari Therapeutics director Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026, to acquire 22,474 American Depositary Shares (ADSs). These exercises involved different price points ($0.0004 and $8.00 per ADS) and were not part ", "url": "https://www.stocktitan.net/sec-filings/AKTX/form-4-akari-therapeutics-plc-insider-trading-activity-dcb548feb591.html", "source_name": "Stock Titan", "published_at": "2026-07-17T09:40:22", "published_display": "17 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Q4 2025 earnings summary", "summary": "Akari Therapeutics (AKTX) reported a Q4 2025 summary highlighting its strategic shift to next-generation antibody-drug conjugates (ADCs) following the acquisition of Peak Bio. The company's lead candidate, AKTX-101, is in preclinical development with a projected Phase 1 trial sta", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-q4-2025_FPwe6lo4", "source_name": "Quartr", "published_at": "2026-07-16T13:40:23", "published_display": "16 Jul 2026 13:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Proxy filing Summary", "summary": "Akari Therapeutics has released a summary of its upcoming 2026 Annual General Meeting (AGM), scheduled for June 30, 2026. The meeting will address 18 resolutions covering financial, governance, compensation, and capital matters, with the Board unanimously recommending a \"for\" vot", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-proxy-filing_FPweVxlU", "source_name": "Quartr", "published_at": "2026-07-16T04:11:56", "published_display": "16 Jul 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Q1 2026 earnings summary", "summary": "Akari Therapeutics (AKTX) reported a Q1 2026 net loss of $14.5 million, significantly higher than Q1 2025 due to non-cash impairment charges. The company is focused on advancing its lead ADC program, AKTX-101, towards a Phase 1 trial by mid-2027 but faces substantial doubt about ", "url": "https://quartr.com/events/akari-therapeutics-plc-aktx-q1-2026_FPweVime", "source_name": "Quartr", "published_at": "2026-07-16T03:11:56", "published_display": "16 Jul 2026 03:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Akari Therapeutics Plc SEC Filing", "summary": "Akari Therapeutics Plc (AKTX) has had an [EFFECT] SEC Filing, indicating the effectiveness of its S-3 shelf registration statement. This filing, accepted by EDGAR on July 14, 2026, and effective on July 13, 2026, allows the company flexibility in future offerings. The filing's se", "url": "https://www.stocktitan.net/sec-filings/AKTX/effect-akari-therapeutics-plc-sec-filing-325b521b90a1.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:11:56", "published_display": "15 Jul 2026 01:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com", "summary": "This article announces the filing of Form S-3/A by Akari Therapeutics PLC on July 10. It is a brief, one-line report from Investing.com, providing basic information about the SEC filing. The article does not contain further details about the content of the S-3/A filing.", "url": "https://ng.investing.com/news/stock-market-news/form-s3a-akari-therapeutics-plc-for-10-july-93CH-2595513", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T00:09:38", "published_display": "11 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement", "summary": "Akari Therapeutics Plc (NASDAQ: AKTX) has filed an amended shelf registration to allow existing holders to resell up to 5.99 million American Depositary Shares (ADSs), representing approximately 479.99 billion ordinary shares. These ADSs originate from a private placement in May ", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-a-akari-therapeutics-plc-amended-shelf-registration-statement-4ee48cfb7f35.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:10:18", "published_display": "10 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics(AKTX) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgJBVV95cUxQajJ6SThaUkgyNTItRDlXTWxiZjBQVXhmcVFnNDI4SlBmMHUzTGhnTFhfTk9fX3NqT2lnRkFiWW9UdWFFMTFoTXdYRmoxVHpHc19zbjlTZWJzYnFEZm80bkc3ZTZFVkpFbTNWNzZNUUNLR3J3cmJpd2pidmhDUV81YVlFUXdDRjMzTlFNdGlmQXpacTB2eERDTThSeXctTHdQSWxiWmRkNlRKSkNPcTAwNVhEdUxtVVJSZUR4eXZObE1ZaFIzdk1aQ3lxSHhHZUEtVlo1dVN2SFBXRWRYSjkxSHNmcG5xelJ1cTF0YWxGTFN3QTNkQmo3cVBqQVpxV19tYl9qMm11SThsbjZ0b2VlV2twQjVEYUVVeVhMNmRwbnA4Q2wyUGtUZW9EZzhydw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-09T15:58:19+00:00", "published_display": "09 Jul 2026 15:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) adds private\u2011placement warrants and purchase agreement exhibits", "summary": "Akari Therapeutics (NASDAQ: AKTX) has amended its S-3 registration statement to file exhibits, including amended Articles of Association, deposit agreement documents for American Depositary Shares, various warrant forms (Pre-Funded, Series H, I, and J), and the Securities Purchas", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-a-akari-therapeutics-plc-amended-shelf-registration-statement-e79c70792202.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:10:03", "published_display": "08 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Appoints Former AACR President and", "summary": "Akari Therapeutics has appointed Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase oncology clinical development will be instrumental as Akari advances", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323219/0/en/akari-therapeutics-appoints-former-aacr-president-and-renowned-oncology-drug-development-leader-patricia-lorusso-d-o-to-scientific-advisory-board.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T22:49:33", "published_display": "07 Jul 2026 22:49", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxNTFNUTWNWY2NqQUNPNDlHT0J4MlZQTWVmbGtoQVlNYTlJMDRueFBzWm55U0ZBM19IYWVuTUgzSk9qMG44U2RDY1lNUHBQMmU3NjY4X3ZveUhGdV8tbDFvTjFUbzREdUdQOTJ5M1drYkluRWtkbDduNHpQVkF3bHBrU1dNUnJpaUhaM0lJWmRXYlpBOGVLQ1JqMFFkQVNtMmZUT0x2eGFrMzlvUFBjeHAySWNNck9YMjgzU2ZGRENaTXZZaUlFem5JMnI5SVpBWHh5b2J5ank0enRqSFNJREcxanlCLUYxUlhqYUM2bmZtSDZuZWVuSDVj?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T21:20:19+00:00", "published_display": "07 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari adds former AACR president Patricia LoRusso to advisory board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPVzNXZHFIVnJ1MTN5eVR1OFpBYm04MDc1S1ZkZUU2MTFDdTVLVVJUcFR0TlNxNVhMSXlPZkM2S0FEbzFfSHlGVV83ZmNTTWNaeEhfOHZ3Y0FERDNOSjkwaXExcE1fdlJnMnlTQ0tUWWY1VDRFbVB2YTFTNFBicE4xUW5IbnRERjdIakt1UDFwU2dwYzgySlltSUI4NTFPZEJ4N25UNWZnMnd3VTQtOU56VkJkSkJwV3Rt?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T12:55:00+00:00", "published_display": "07 Jul 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board", "summary": "Akari Therapeutics, an oncology biotechnology company, announced the appointment of Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase clinical developm", "url": "https://www.finanznachrichten.de/nachrichten-2026-07/68963740-akari-therapeutics-plc-akari-therapeutics-appoints-former-aacr-president-and-renowned-oncology-drug-development-leader-patricia-lorusso-d-o-to-sc-399.htm", "source_name": "FinanzNachrichten.de", "published_at": "2026-07-07T13:09:32", "published_display": "07 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board", "summary": "Akari Therapeutics, an oncology biotechnology company, has appointed Dr. Patricia LoRusso, a globally recognized leader in oncology drug development, to its Scientific Advisory Board. Dr. LoRusso's extensive expertise will be crucial as Akari advances its lead candidate, AKTX-101", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323219/0/en/Akari-Therapeutics-Appoints-Former-AACR-President-and-Renowned-Oncology-Drug-Development-Leader-Patricia-LoRusso-D-O-to-Scientific-Advisory-Board.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T12:41:30", "published_display": "07 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside", "summary": "Akari Therapeutics (AKTX) shares surged over 133% after reporting positive preclinical data for its lead cancer therapy, AKTX-101, and announcing a $5.5 million private placement. AKTX-101 showed strong results in pancreatic cancer cells when combined with an existing drug. The c", "url": "https://stocktwits.com/news-articles/markets/equity/aktx-stock-goes-parabolic-after-hours-on-capital-raise-cancer-data-win/cZgbrxiRe8F", "source_name": "Stocktwits", "published_at": "2026-07-07T11:09:32", "published_display": "07 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) AGM OKs new share issuances and board changes", "summary": "Akari Therapeutics shareholders approved several key proposals at their June 30, 2026 Annual General Meeting, including the 2025 financial statements, most director re-elections, and the appointment of auditors. Critically, shareholders also approved significant equity-related it", "url": "https://www.stocktitan.net/sec-filings/AKTX/8-k-akari-therapeutics-plc-reports-material-event-dc3de81ad81e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:06", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3 Akari Therapeutics PLC For: 2 July By Investing.com", "summary": "Akari Therapeutics PLC filed a Form S-3 on July 2nd. The article provides the filing information and mentions that the company's stock symbol is AKTX, which was up 1.56% at the time of publication. The content itself seems to be a template for financial news with many market data", "url": "https://ca.investing.com/news/stock-market-news/form-s3-akari-therapeutics-plc-for-2-july-93CH-4719213", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:41:06", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each", "summary": "Akari Therapeutics (NASDAQ: AKTX) has registered 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares, for resale by selling shareholders. These ADSs arise from a May 2026 private placement and include shares issuable upon the exercise of vari", "url": "https://www.stocktitan.net/sec-filings/AKTX/s-3-akari-therapeutics-plc-shelf-registration-statement-b0633e0d7426.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:09:20", "published_display": "02 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics PLC has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC)", "summary": "Akari Therapeutics PLC has filed a prospectus supplement with the SEC concerning the resale of up to 6 million American Depositary Shares (ADS) by existing shareholders. These ADS represent up to 48 billion ordinary shares. The company will not receive any proceeds from this tran", "url": "https://www.bitget.com/amp/news/detail/12560605487904", "source_name": "Bitget", "published_at": "2026-07-02T09:11:01", "published_display": "02 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones", "summary": "Akari Therapeutics announced the completion of its $5.5 million PIPE early by consolidating remaining funding tranches, along with an additional $2.8 million from warrant exercises, totaling approximately $8.3 million in Q2 2026. This capital injection strengthens the company's f", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/akari-therapeutics-completes-previously-announced-pipe-strengthening-balance-sheet-ahead-of-potential-key-clinical-and-regulatory-milestones/2374900", "source_name": "The Manila Times", "published_at": "2026-06-30T08:39:11", "published_display": "30 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics completes $8.3m capital raise in Q2", "summary": "Akari Therapeutics Plc (NASDAQ:AKTX) successfully completed a private placement and warrant exercises, raising approximately $8.3 million in total capital during the second quarter of 2026. This capital infusion is significant for the oncology biotechnology company, which is deve", "url": "https://www.investing.com/news/company-news/akari-therapeutics-completes-83m-capital-raise-in-q2-93CH-4765464", "source_name": "Investing.com", "published_at": "2026-06-30T08:09:13", "published_display": "30 Jun 2026 08:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKTX - Akari Therapeutics Plc ADR Options", "summary": "This article provides a detailed financial overview of Akari Therapeutics Plc (AKTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutiona", "url": "https://finviz.com/stock?t=AKTX&p=m&ty=oc&r=y5&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-06-29T20:41:01", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Completes Previously Announced PIPE,", "summary": "Akari Therapeutics announced the completion of its $5.5 million PIPE combined with an additional $2.8 million from warrant exercises, totaling $8.3 million in Q2 2026. This funding strengthens the company's balance sheet, supporting the advancement of its lead candidate AKTX-101 ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318968/0/en/akari-therapeutics-completes-previously-announced-pipe-strengthening-balance-sheet-ahead-of-potential-key-clinical-and-regulatory-milestones.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com", "summary": "Akari Therapeutics (NASDAQ: AKTX) has successfully completed an $8.3 million capital raise in Q2 2026, comprising a $5.5 million private investment in public equity (PIPE) led by existing investors and $2.8 million from warrant exercises. This funding is critical for the oncology", "url": "https://ca.investing.com/news/stock-market-news/akari-therapeutics-completes-83m-capital-raise-in-q2-93CH-4711813", "source_name": "Investing.com Canada", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari locks in $8.3M to fund cancer drug trial push", "summary": "Akari Therapeutics announced the completion of an $8.3 million funding round in Q2 2026, comprising a $5.5 million PIPE and $2.8 million from warrant exercises. This capital infusion is intended to advance its lead drug candidate, AKTX-101, towards a Phase 1 clinical trial and pr", "url": "https://www.stocktitan.net/news/AKTX/akari-therapeutics-completes-previously-announced-pipe-strengthening-jebqw2qjgozp.html", "source_name": "Stock Titan", "published_at": "2026-06-29T13:12:50", "published_display": "29 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com", "summary": "This article announces that Akari Therapeutics PLC filed a Form S-1/A on June 26. The news is brief and directly states the filing, indicating it's a financial regulatory update for the company. The article also includes various market data and related news not directly tied to t", "url": "https://ng.investing.com/news/stock-market-news/form-s1a-akari-therapeutics-plc-for-26-june-93CH-2576646", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T19:40:12", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Amends Securities Purchase Agreement in June 2026 \u2013 Key Details from Latest 8-K Filing", "summary": "Akari Therapeutics, Plc has amended its Securities Purchase Agreement, consolidating the second and third closings into a single \"Combined Closing\" for an aggregate investment. This amendment, detailed in a Form 8-K filing, requires shareholder approval at the company's annual ge", "url": "https://www.minichart.com.sg/2026/06/27/akari-therapeutics-amends-securities-purchase-agreement-in-june-2026-key-details-from-latest-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-27T01:09:27", "published_display": "27 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Consolidates Private Placement Closings; Issues 980,395 ADSs in Final Tranche", "summary": "Akari Therapeutics (AKTX) has amended its Securities Purchase Agreement to consolidate the second and third closings of its private placement into a single closing on June 26, 2026. The company issued 980,395 additional ADSs (or prefunded warrants) in this final tranche, bringing", "url": "https://www.tradingview.com/news/tradingview:3e5c2f35a9d9d:0-akari-therapeutics-consolidates-private-placement-closings-issues-980-395-adss-in-final-tranche/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:27", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (NASDAQ: AKTX) consolidates private placement closings, issues remaining ADSs", "summary": "Akari Therapeutics (NASDAQ: AKTX) has amended its securities purchase agreement to combine the second and third closings of a private placement into a single consolidated closing on June 26, 2026. This private placement involves 1,470,588 unregistered American Depository Shares (", "url": "https://www.stocktitan.net/sec-filings/AKTX/8-k-akari-therapeutics-plc-reports-material-event-a146d446be88.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:09:27", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX)", "summary": "This page on TradingView provides financial actuals and estimates for Akari Therapeutics Plc (NASDAQ: AKTX). Users can explore reported financial data and analyst estimates, across various financial statements and valuation metrics. The platform allows for comparison of actual re", "url": "https://www.tradingview.com/symbols/NASDAQ-AKTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:40:35", "published_display": "26 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Akari Therapeutics PLC For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU01YVnk4NkVhYXhTajAzX0twVEVZWmNRV1dPbEN1U3JaZExER1ZlZnJKbENCckxLWjZPSDgyRF9NU3JrYVo5SzZRQm9YbjZoUnlPR2VvODEwYVpRd3lZandjbEdyZGtVQW13M3NXOUthVkhBeWY3Zy1OcXB5VVh0a2JyRWNDNTBCX1lkRlA5UDNlR0VYQXNITUduNk9EdTdicW5QOA?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-26T01:21:14+00:00", "published_display": "26 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Akari Therapeutics Stock Is Falling On Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOcjBRcTFlWnRHeVg5TktFaVk0cjItRUkzMHNiS2pDTUFOUlR5SFE1UTIyaURFbHNxaGRYYWk1SmNTbGJkZTVxSDRvN0ZPdXZKLUdMNHgwanlhb2JTQ2p2RUlGdVFIdkE2SzVLMjlNMGRnbUtsQ1hLVkozdHdzWFRVOVBucFRiR1ZZZVpXMHg2VXcxb1Bua0Y1amtXRDMyNDNYX203RFRPWTNHdFktT3VDQQ?oc=5", "source_name": "Benzinga", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attention", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPNFFuQTlMeWNFandpN1dITUNYZFhCTVRhNDl0UF9QZldJdEZJZjk4cWF0NEw5U0xuRDBwSURkQXMxYkpxT0t5cU9Venk0TTUzWGVZMk10bDBOdWlUUm5hNUs1SnVUWF9rbGZlaTFlOS1zOGRJVGdELUpiNk92bTQyd3hkNy1TVHFKaXh6UkkwMVRjVy13bmpLX2pwN3E0RlVnb2tkbHlmRmRHNmZkYmh3WkZUQjdmSUFCUjZ3dlVXU1pFWWoxbWo2dVhJZmRySEpibGlsVjdDbGYzVEcydlFtSDdTZW4wanM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$5.5M raise to push Akari cancer drug toward first human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPWEpseGJYY0xUMURZeVh2NXBYbXMwZ3pXd0lrdkpnTzlkOEFMQTlHOW1vMU1KMmJZcnhvbE5BNjNwMUxuSFNFdllVUThUbm5NYUNiMlJTeDVBQ3p0X2RpZmpXdUY5UVIyNVhqN19DRUtPUFlQZ1ZJcWtTaXlIVDVMWkk4N2NoeFBJRGw1OGRfb1FVcExTZHRoWkFxLThUZkd6dFkwa1h1TFhZMW0zeFBTSXNBMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics stock rockets 50% higher on KRAS combination data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWGYzODYzZUJBeDNBcmJieHRSSElvRnV0ZER1MUpqb1FFRDdYZ3VIY05CanU5VmxXS1lqU3VNYUdJc28zTXpham04ZFM1dnRSRWRlTW91a0xIQkdFakxuSXhGWVN3MHdzQ0JKRUZ2T0pZdF9uUkF1TkUwaXhvektJSmNJOHhJNW9pMW5WSzdmTjlOV0l2eXJUSVdSV09vOVJqUkl3X2U2UW8tRVhEOHV3WW9JYXUtT1A1Ymx3ZWdKd3BqVFdld3Vrbg?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Shares Surge 120% on Promising Preclinical Cancer Therapy Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPRVBlYldtOFR1QUl5V3F0b2dsdnY4OUpxT0lUNVZxSUw5cklvNEZDaUJHUmpnV1BJMU55bnkwZGpfSHEzeHo3QTlvY0ZXdktXb05zUUtqTlJyc1ZrVDlZOGVheHJRUTNrazhpWWJBTkRTTTIwZ3FaRXNrRkZXN3MwaS14ZE0zY2JISlpIODlJNVFuUFJfXzJFemZVY0d2X0VkekRUSURPZmh4dXY2UDJwNUlCWnd3clc1OWI5S2Z3QnpOZEFxcFBkWTA3aWFNYmF2bkE?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[RW] Akari Therapeutics Plc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNNkI3dlRnN1ZtMzlJZGRxVmlzei1IbWdqemRUNG9WOTVBMDZLQjhVX3BxMGV5LXc2bU5ZVGhIVmtsb1hyS25MZTRmYUVZNUdkYlctaTNBMTBIc1RaemZGVGZRM3VWLXpDWWNfaGEtN0MyQjlpYjFOa09ReUw0Q2hlOG1teWcxWklNY0QwcF9PN2FWQl95NnBhbWpsbGJXblU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental Akari drug boosts KRAS blocker in pancreatic cancer cells", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaUF5N2ozOUJGUDlYOE5wVWRZa05hV3lGck5YMlh3cy1YRmV2X1JncTg2V01ybDc1bVFqOGRHOHF4WU9TY1QxMXRzb3VLYWk1djZJbEZIM2plM3BBNnQ5dHByeEIwTXlBUzZEa0hDYlhGMUx1MjkxTjlsdnJFVTd4RXVvc0NZYmNhbmhQYkZRb1hvaE5vSW5UUXlxaXYwQnNOTGwtbUhZZE5iZmNqVHRCVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari adds Australian patent cover for payload behind two cancer programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNV2JFbVN0ZjJFRjZackhubVZ2MkE3N2w0M1JodTMyTm5ZUnFVVlAtU0J2X0liTmZXYXdoRHhiNjR4dHNkZFdlaTRhWkNIczVXcGk5WVlldUx4ZUtJTU40VTZtMGdsc2lCT2VvbmVPUk4wMTlURDF6OWo0V0IzNG1qZm1mLTJqTm1pUmZfclViUm1GTXk2bG85VUdIaVR0LTNYeTRkVDdDN1EyNUM5alYwbFdyR2oya1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bladder, lung and breast models show Akari drug beats TROP2 rivals", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWXBERFpjTjVTSjkzVUdwUGh4TmsyV1hfU2JYV3RjdlJwQXJ2aE5XTnYtc0dKWFpUUkhmRXVwYnNWbGRVeHpsZmRHOTFlZkZjRThvbHUxRGdicXlnSUhDblZGVkxFMHRRM1ZWdmpQSWZWcDM2S1VIc1Fwa1FZejIxNWNZNUZsUW1uMXZLZkF5NGlZdHJBRXdJaTFCQW1LUGotajNGdXhiZ29PU3lfMU5yRlBJbWZyeUlfa2ZmbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer biotech Akari charts new ADC toward first human trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPVlZLTG1GcUk0MXpxMGp1cjdGbWk3WWU4ZmRvZmhDeVBJdU5pUDctdzdzSlR4Qy1rRVkzVWM4ZlNMdjBraDVEMDVTVkxJUm5yeU50Z080UG91WTJVODk3OVIwZXpOckhrVk9oV2E0V0VhdXlrektRTG9FQmxidk51ZEh6TGJRUWF3RE1RV0kyYlQ3RS1veXhtbWNNc3lod2pjeEwya3RrYmFIRUVfUlJoVWxlNWxOdVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Purchased US$1.81m Of Akari Therapeutics Stock May Not Have Expected 36% Tumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE91UXVJV2l5dF9rNnUzcDZObGVLdW9ENTBaOWgxVktHeTduQVNJb3MwbldyM0tQR29wLVRxSWlCZVhDak55SE4ydVRpd0RfQ29iN0hqa3dkRDFQNVhKbG1sRHRWckhvS2p6WUR2QnBtX0RUQ3J5YWJTazFXNTF3QQ?oc=5", "source_name": "Market source", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-14T08:00:00+00:00", "published_display": "14 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics Plc (AKTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBMUTFxRmkta3NHcS00Ylk0SVo5aTRMSUlBY3pYV2hMNUVtSDZaNWk0U1ZqM21sSVdRQnhWTFNmNWI4Z0lTNEFJUGllSWNlRHN5bmtz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:27:43+00:00", "published_display": "25 Apr 2025 00:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akari Therapeutics (AKTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1oaW1aQ0NKWW5OQUZUbVo1ZjBVNzFrUXJwSHZNNmhZMnNzaHM4MkJvR0VIaVdxbGJNck5RZ3ZrYzBGUmFzZU5Vd0JabEFMUUJjemFxTmI1bFFxQQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-11T23:18:55+00:00", "published_display": "11 Aug 2016 23:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 55, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 36, "score": 53, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 20.35, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 13.88, "latest_week": "2026-07-10", "one_week_move": 33.3, "four_week_move": 3.6, "twelve_week_move": 139.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.034085, "market_dynamics_buy_signal": true, "relative_strength": -38.586222, "fair_value_gap": -79.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.532, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+33.3% over one week, +3.6% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Market Dynamics buy signal", "Value support"], "opportunities": ["Market Dynamics is showing a buy signal in the latest weekly context.", "Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "Market source", "count": 7}, {"label": "Quartr", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Investing.com Canada", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+33.3% over one week, +3.6% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Akari Therapeutics PLC For: 17 July By Investing.com"}], "updated_at": "2026-07-18T00:59:00.543871+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}